Stockscreener 앱 받기
4.12
0.49%
0.02
시장 영업 전:
4.03
-0.09
-2.18%
전일 마감가:
$4.10
열려 있는:
$4.16
하루 거래량:
58,279
Relative Volume:
1.10
시가총액:
$326.36M
수익:
-
순이익/손실:
$-18.50M
주가수익비율:
-15.91
EPS:
-0.259
순현금흐름:
$-11.89M
1주 성능:
+7.57%
1개월 성능:
-27.08%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.00
$4.19
1주일 범위
$3.8401
$4.24
52주 변동 폭
$3.73
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
4.12 | 324.77M | 0 | -18.50M | -11.89M | -0.259 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nervgen Pharma Corp 주식(NGEN)의 최신 뉴스
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program - TipRanks
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - GlobeNewswire
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium - Yahoo! Finance Canada
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development - MSN
NervGen Pharma appoints Dr. Adam Rogers as CEO and president By Investing.com - Investing.com Australia
NervGen Pharma appoints Dr. Adam Rogers as CEO and president - Investing.com
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal - TipRanks
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury - marketscreener.com
NervGen Pharma names Adam Rogers as CEO - The Pharma Letter
NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase - TipRanks
NervGen appoints Rogers as CEO to lead neuroreparative drug development By Investing.com - Investing.com Australia
NervGen Pharma Names Adam Rogers Permanent CEO to Drive Next Growth Phase - TipRanks
NervGen Pharma Appoints New CEO Adam Rogers - Intellectia AI
NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291 - GuruFocus
NervGen Pharma Names Adam Rogers as CEO - marketscreener.com
NervGen appoints Rogers as CEO to lead neuroreparative drug development - Investing.com
NervGen Pharma Corp appoints Adam Rogers as chief executive officer - marketscreener.com
NervGen Pharma Corp. Appoints Adam Rogers as Chief Executive Officer, Effective February 9, 2026 - marketscreener.com
New drug may help spinal cord injury patients regain function and hope - WGN-TV
When Will NervGen Pharma Corp. (CVE:NGEN) Breakeven? - Yahoo Finance
Johnson & Johnson receives CHMP positive opinion for AKEEGA - marketscreener.com
Analysts Expect Breakeven For NervGen Pharma Corp. (CVE:NGEN) Before Long - simplywall.st
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
NervGen Pharma Rings the Closing Bell - Nasdaq
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing - GlobeNewswire
NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment - MSN
NervGen Pharma Begins Trading on Nasdaq Today - Sahm
Is NervGen Pharma Corp. (9UA) stock good for wealth creationJuly 2025 Movers & Weekly High Conviction Trade Ideas - Улправда
NervGen Pharma Debuts On Nasdaq - Nasdaq
NervGen Pharma to Begin Trading on Nasdaq - marketscreener.com
NervGen Pharma Lists on Nasdaq to Support Late-Stage Push for Spinal Cord Injury Drug - TipRanks
NervGen Pharma Gets Approval for Listing on Nasdaq - marketscreener.com
NervGen Pharma Brief: Begins Trading on Nasdaq Today - marketscreener.com
Sector Update: Health Care Stocks Edge Higher Late Afternoon - marketscreener.com
Sector Update: Health Care Stocks Mixed Late Afternoon - marketscreener.com
This Company’s Drug May Help Regenerate Injured Spinal Cords - Forbes
NervGen Pharma Files SEC Registration to Advance Strategic Growth - TipRanks
NervGen Pharma Announces Proposed Amendment to Warrants - Yahoo Finance
This Canadian biotech stock is looking to treat spinal cord injuries - Cantech Letter
NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment - TipRanks
Data back spinal injury bid from Nervgen in phase Ib/IIa - BioWorld MedTech
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development - TMX Newsfile
NervGen Pharma Secures $10 Million to Propel Nasdaq Listing and NVG-291 Development - TipRanks
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development - TMX Newsfile
Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth? - Yahoo Finance
Pennsylvania man says experimental drug has helped him recover from cycling accident - CBS News
Nervgen Pharma’s NVG-291 Study: A Potential Breakthrough in Spinal Cord Injury Treatment - TipRanks
NervGen Pharma price target chopped at Research Capital - Cantech Letter
NervGen: A High-Stakes Bet on a Groundbreaking Nerve Repair Drug - NAI500
TSX Penny Stocks To Consider In August 2025 - Yahoo Finance
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury - Yahoo Finance
Nervgen Pharma Corp (NGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):